High-Density Lipoproteins in Kidney Disease

Abstract

Decades of epidemiological studies have established the strong inverse relationship between high-density lipoprotein (HDL)-cholesterol concentration and cardiovascular disease. Recent evidence suggests that HDL particle functions, including anti-inflammatory and antioxidant functions, and cholesterol efflux capacity may be more strongly associated with cardiovascular disease protection than HDL cholesterol concentration. These HDL functions are also relevant in non-cardiovascular diseases, including acute and chronic kidney disease. This review examines our current understanding of the kidneys' role in HDL metabolism and homeostasis, and the effect of kidney disease on HDL composition and functionality. Additionally, the roles of HDL particles, proteins, and small RNA cargo on kidney cell function and on the development and progression of both acute and chronic kidney disease are examined. The effect of HDL protein modification by reactive dicarbonyls, including malondialdehyde and isolevuglandin, which form adducts with apolipoprotein A-I and impair proper HDL function in kidney disease, is also explored. Finally, the potential to develop targeted therapies that increase HDL concentration or functionality to improve acute or chronic kidney disease outcomes is discussed.

Keywords: acute kidney disease; apolipoprotein AI; chronic kidney disease; high-density lipoprotein (HDL); isolevuglandins; malondialdehyde; sRNA.

Figure 1

Kidney handling of normal and modified apoAI/HDL by the glomerulus, tubule epithelium, and renal interstitium involves (1) filtration (2) tubular uptake (3) transcytosis (4) transport by lymphatic vascular network in interstitium and (5) urinary excretion.

Figure 2

The effects of CKD on HDL structure and function, and the therapeutic implications.